Method Development of NDMA and NDEA Quantification in Sartan Drug by LC-MS/MS

Nitrosamine Impurities Application Guide Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products Sartan-Based Losartan Valsartan Candesartan Telmisartan Metformin Ranitidine Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse…

Application Note Pharmaceuticals Highly Sensitive LC/MS/MS Method for the Simultaneous Quantification of Mutagenic Azido Impurity Analogues in Five Different Sartan APIs and Formulations Detection of regulated genotoxic impurities from the drug manufacturing process Authors Kartheek Srinivas Chidella, Saikat Banerjee, and…

Application Note Pharmaceutical Determination of Nitrosamines in Active Pharmaceutical Ingredients High flexibility and performance at lowest cost using the Agilent 1260 Infinity II Prime LC with the Agilent Ultivo LC/TQ for LC/MS analysis Author Edgar Naegele Agilent Technologies, Inc. Abstract…

Application News No. AD-0199 Drug Contaminants / GCMS-TQ8050 NX Determination of Nitrosamine Impurities in Sartan Drug Products by GC-MS/MS Method Crystal Yeong and Cynthia Lahey ❑ Introduction Table 1. GC-MS/MS analytical conditions Drugs containing sartan APIs (active pharmaceutical ingredients), such…